These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 2670296)
1. Current status of allergen immunotherapy (hyposensitization): memorandum from a WHO/IUIS meeting. Bull World Health Organ; 1989; 67(3):263-72. PubMed ID: 2670296 [TBL] [Abstract][Full Text] [Related]
2. Current status of allergen immunotherapy (hyposensitization). Report of a WHO/IUIS working Group. Allerg Immunol (Leipz); 1989; 35(4):235-47. PubMed ID: 2696375 [No Abstract] [Full Text] [Related]
3. The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy; 1989 Aug; 44(6):369-79. PubMed ID: 2679219 [No Abstract] [Full Text] [Related]
4. [Hyposensitization: indications and expectations]. Urbanek R Padiatr Padol; 1990; 25(6):397-404. PubMed ID: 2080061 [TBL] [Abstract][Full Text] [Related]
5. [Status report on allergen immunotherapy (hyposensitisation). Prepared by the WHO/IUIS Immunotherapy Subcommittee 1988]. Malling HJ Ugeskr Laeger; 1989 Nov; 151(48):3249-52. PubMed ID: 2595857 [No Abstract] [Full Text] [Related]
6. [Current aspects of hyposensitization]. Albegger K HNO; 1990 Jul; 38(7):233-41. PubMed ID: 2203718 [TBL] [Abstract][Full Text] [Related]
7. Local reactions from subcutaneous allergen immunotherapy. Coop CA Immunotherapy; 2013 Dec; 5(12):1339-45. PubMed ID: 24283844 [TBL] [Abstract][Full Text] [Related]
8. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet; 1989 Feb; 1(8632):259-61. PubMed ID: 2563421 [No Abstract] [Full Text] [Related]
9. Immunological mechanisms of allergen-specific immunotherapy. Larché M; Akdis CA; Valenta R Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509 [TBL] [Abstract][Full Text] [Related]
11. [What is reliable in hyposensitization of IgE-induced diseases? Indications, contraindications, results and side effects]. Fuchs T Internist (Berl); 1991 Dec; 32(12):721-8. PubMed ID: 1783514 [No Abstract] [Full Text] [Related]
12. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy. Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007 [No Abstract] [Full Text] [Related]
13. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases]. Malling HJ Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284 [TBL] [Abstract][Full Text] [Related]
18. [The value of immunotherapy in treatment of IgE-induced allergic diseases]. Müller UR Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841 [TBL] [Abstract][Full Text] [Related]
19. Hyposensitization (immunotherapy) in allergic diseases: an introduction. Fuchs E Allergol Immunopathol (Madr); 1981; Suppl 9():167-70. PubMed ID: 7349726 [No Abstract] [Full Text] [Related]
20. Future Horizons in Allergy. Marino MJ; Luong AU Otolaryngol Clin North Am; 2017 Dec; 50(6):1185-1193. PubMed ID: 28992950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]